Back to top
more

Alkermes (ALKS)

(Real Time Quote from BATS)

$27.12 USD

27.12
746,353

+0.53 (1.99%)

Updated Oct 10, 2024 02:18 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (84 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain Amedisys (AMED) Stock for Now

by Zacks Equity Research

Investors are optimistic about the robust performances of Amedisys' (AMED) Home Health and Hospice segments.

Pfizer (PFE) Reports More Positive Data From Etrasimod Study

by Zacks Equity Research

Pfizer (PFE) states that data from the ELEVATE 12 and ELEVATE 52 studies will form the basis of the regulatory submissions on etrasimod expected later this year

Merck (MRK) Keytruda Gets EU Nod for Expanded Breast Cancer Use

by Zacks Equity Research

The European Commission approves Merck's (MRK) Keytruda for high-risk early-stage TNBC, which expands its eligible patient population.

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication (Revised)

by Zacks Equity Research

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

Entasis (ETTX) Stock Rises on Buyout Offer From Innoviva

by Zacks Equity Research

Innoviva (INVA) is set to acquire Entasis (ETTX) for $2.20 per share in cash. The transaction is likely to close by third-quarter 2022.

Shockwave Medical's (SWAV) IVL Cleared for Use in China

by Zacks Equity Research

Shockwave Medical's (SWAV) latest regulatory approval is expected to serve a wider patient pool.

Abbott (ABT) Transcatheter Valve Devices' Study Data Favorable

by Zacks Equity Research

Abbott's (ABT) study data presented at EuroPCR 2022 reinforces the company's commitment to offering structural heart solutions, supported by clinical evidence that exceeds existing standards of care.

Biohaven's (BHVN) Zavegepant NDA for Migraine Accepted by FDA

by Zacks Equity Research

The FDA accepts Biohaven's (BHVN) NDA seeking approval for its pipeline candidate, zavegepant, as an intra-nasal treatment for migraine. A decision is expected early next year.

Athersys (ATHX) Down as Ischemic Stroke Study Fails to Meet Goal

by Zacks Equity Research

While a mid-stage/late-stage study evaluating Athersys' (ATHX) stem cell treatment for ischemic stroke misses out on its primary endpoint, top-line data shows evidence of therapeutic impact.

Regeneron's (REGN) Evkeeza Positive in Late-Stage Study

by Zacks Equity Research

Regeneron (REGN) announces positive data on a phase III study on cholesterol treatment Evkeeza.

Novartis (NVS) Cosentyx Gets Positive CHMP Opinion for JIA

by Zacks Equity Research

Novartis (NVS) Cosentyx gets a positive CHMP recommendation for the indication of juvenile idiopathic arthritis.

Here's Why You Should Hold on to Exact Sciences (EXAS) Stock

by Zacks Equity Research

Investors are optimistic about Exact Sciences (EXAS) on impressive Q1 results and a bullish 2022 outlook.

Sanofi, Regeneron's Dupixent Gets FDA Nod for 4th Indication

by Zacks Equity Research

The FDA approves Sanofi's (SNY) Dupixent for treating adults and children aged 12 and older with eosinophilic esophagitis, a chronic, progressive inflammatory disease.

Merck's (MRK) Keytruda Gets CHMP Nod for Expanded Melanoma Use

by Zacks Equity Research

Merck's (MRK) anti-PD-1 therapy Keytruda nears potential approval as an adjuvant treatment for adolescent pediatric patients with stage IIB, IIC or III melanoma following complete resection.

Radius (RDUS), Menarini Post Positive Data on Breast Cancer Drug

by Zacks Equity Research

Radius (RDUS) and partner Menarini announce data from a late-stage study on breast cancer drug.

Dynavax (DVAX) Up as EMA Accepts Valneva's COVID-19 Vaccine MAA

by Zacks Equity Research

Dynavax (DVAX) gains as the EMA accepts partner Valneva's MAA for COVID-19 vaccine.

LabCorp (LH) Introduces Latest Assay for Skin Cancer Patients

by Zacks Equity Research

LabCorp's (LH) new assay is claimed to have shown a demonstrable clinical advantage in patients suffering from melanoma.

Enanta's (ENTA) RSV Drug Fails to Meet Study Goal, Stock Drops

by Zacks Equity Research

While a mid-stage study evaluating Enanta's (ENTA) RSV candidate misses out on its primary endpoint, a statistically huge number of subjects achieved undetectable RSV RNA at the end of treatment.

Endo (ENDP) Crashes 46.54% as it Looks to Restructure Debt

by Zacks Equity Research

Endo (ENDP) plunges on reports of negotiations with its lenders and senior bondholders about a possible restructuring of more than $8 billion of debt.

Here's Why You Should Retain QIAGEN (QGEN) Stock for Now

by Zacks Equity Research

Investors are optimistic about QIAGEN (QGEN), owing to strong international growth and bullish guidance.

Has Alkermes (ALKS) Outpaced Other Medical Stocks This Year?

by Zacks Equity Research

Here is how Alkermes (ALKS) and Actinium Pharmaceuticals (ATNM) have performed compared to their sector so far this year.

Merck (MRK) Outperforms Industry This Year So Far: Here's Why

by Zacks Equity Research

Strong sales of key products like Keytruda and Gardasil, a significant contribution from Lagevrio and positive pipeline/regulatory developments have been keeping Merck's (MRK) stock afloat in 2022.

AVROBIO (AVRO) Stock Up on Upbeat Data From Cystinosis Study

by Zacks Equity Research

Results from AVROBIO's (AVRO) phase I/II study, which is evaluating its gene-therapy candidate for cystinosis, show the latter's potential to stabilize or reduce the impact of cystinosis on different tissues.

Reasons to Add Patterson Companies (PDCO) Stock to Your Portfolio

by Zacks Equity Research

Investors remain optimistic about Patterson Companies (PDCO) on the back of its strong product line.

Illumina's (ILMN) GRAIL, Intermountain Healthcare Expand Tie-Up

by Zacks Equity Research

Illumina (ILMN) subsidiary GRAIL's MCED blood test will be offered along with existing single cancer screenings to advance cancer care delivery through early detection.